Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADAG Adagene

Pre-Mkt 04-13 04:37:29 EDT

3.80

-0.04

-1.17%

High3.99	Low3.56	Vol298.59K
Open3.80	D1 Closing3.85	Amplitude11.18%
Mkt Cap251.08M	Tradable Cap163.80M	Total Shares66.07M
T/O1.13M	T/O Rate0.69%	Tradable Shares43.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADAG","market":"US","secType":"STK","nameCN":"Adagene","latestPrice":3.8,"timestamp":1775851200000,"preClose":3.845,"halted":0,"volume":298588,"delay":0,"changeRate":-0.011703511053316091,"floatShares":43105200,"shares":66072600,"eps":-0.375,"marketStatus":"Pre-Mkt","change":-0.045,"latestTime":"04-13 04:37:29 EDT","open":3.8,"high":3.99,"low":3.56,"amount":1132525.1743680001,"amplitude":0.111834,"askPrice":3.95,"askSize":200,"bidPrice":3.49,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.375,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776087000000},"marketStatusCode":1,"adr":0,"adrRate":1.25,"listingDate":1612846800000,"exchange":"NASDAQ","adjPreClose":3.8,"postHourTrading":{"tag":"盘后","latestPrice":3.81,"preClose":3.8,"latestTime":"18:58 EDT","volume":287,"amount":1092.51,"timestamp":1775861930654,"change":0.01,"changeRate":0.002632,"amplitude":0.002632},"volumeRatio":0.397917064738565},"requestUrl":"/m/hq/s/ADAG","defaultTab":"news","newsList":[{"id":"2627489653","title":"New Adagene Immuno‑Oncology Tie‑Up Could Be A Game Changer For Incyte (INCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627489653","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627489653?lang=en_us&edition=fundamental","pubTime":"2026-04-13 12:40","pubTimestamp":1776055228,"startTime":"0","endTime":"0","summary":"In April 2026, Adagene Inc. announced it had entered a clinical collaboration with Incyte to test muzastotug (ADG126) with Incyte’s TGFβR2 × PD‑1 bispecific antibody INCA33890 in a Phase 1 trial for third‑line microsatellite stable colorectal cancer, including patients with and without liver metastases, with Incyte sponsoring and running the study.\nThis collaboration highlights Incyte’s continued push into complex immuno‑oncology combinations and positions muzastotug as a potential backbone...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/new-adagene-immunooncology-tieup-could-be-a-game-changer-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/new-adagene-immunooncology-tieup-could-be-a-game-changer-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4532","INCY","BK4139","ADAG","BK4550","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625674940","title":"Adagene: Deepening Dose‑Response Evidence and Strategic Partnership Support Buy Rating on Lead CTLA‑4 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674940","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674940?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:15","pubTimestamp":1775481328,"startTime":"0","endTime":"0","summary":"In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Adagene, with a price target of $8.00. Charles Zhu has give...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/adagene-deepening-dose‑response-evidence-and-strategic-partnership-support-buy-rating-on-lead-ctla‑4-program-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/adagene-deepening-dose‑response-evidence-and-strategic-partnership-support-buy-rating-on-lead-ctla‑4-program-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625867992","title":"Adagene Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2625867992","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625867992?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:05","pubTimestamp":1775477100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADAG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 08:05 ET (12:05 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625768916","title":"Adagene price target raised to $10 from $9 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2625768916","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625768916?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:45","pubTimestamp":1775472327,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Adagene (ADAG) to $10 from $9 and keeps a Buy rating on the shares. The firm is updating its model for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-price-target-raised-to-10-from-9-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-price-target-raised-to-10-from-9-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624504321","title":"Sector Update: Health Care Stocks Decline Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2624504321","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624504321?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:19","pubTimestamp":1775135950,"startTime":"0","endTime":"0","summary":"Health care stocks were declining premarket Thursday, with the State Street Health Care Select Sector SPDR ETF  0.7% lower and the iShares Biotechnology ETF  down 1.6%.Immunovant  shares were down more than 10% after the company said topline results from two phase 3 clinical studies of batoclimab as an experimental treatment of thyroid eye disease in adults showed that they failed to meet their primary endpoint.Novo Nordisk  said its 25 mg Wegovy pill demonstrated \"significantly greater\" mean weight loss than Eli Lilly's  36 mg orforglipron, which was approved by the Food and Drug Administration under the brand name Foundayo. Shares of Novo Nordisk were down more than 1% pre-bell.Adagene  stock was down more than 15% after the company priced an underwritten public offering of about 18.7 million American depositary shares at $3.75 apiece, for gross proceeds of roughly $70 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0109394709.USD","LU0640476718.USD","LU2237443895.HKD","LU0471298777.SGD","IE00BK4W5M84.HKD","LU2756315318.SGD","LLYZ","LU1061106388.HKD","SGXZ51526630.SGD","IE0005OL40V9.USD","LU2361044865.SGD","SGXZ99366536.SGD","ELIL","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU1623119135.USD","LU1974910355.USD","LU2491049909.HKD","LU0122379950.USD","IMVT","LU0456855351.SGD","IE00B1BXHZ80.USD","LU2265009873.SGD","LU2324357040.USD","XBI","IE0001KFT4U8.USD","LU0432979614.USD","LU0097036916.USD","BK4599","LU0225283273.USD","LU0689472784.USD","LU2108987350.USD","LU0708995401.HKD","LU0096364046.USD","LU0238689110.USD","LU0471298694.HKD","LU1280957306.USD","LU1323610961.USD","LU2552382132.HKD","LU2168563687.JPY","LU1804176565.USD","LU1551013425.SGD","LLYX","LABU","LU2063271972.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE00B7KXQ091.USD","NVO","LU0256863811.USD","LU0316494557.USD","LU2746668461.USD","BK4585","LU1868836591.USD","LU0154236417.USD","IE00B775H168.HKD","LU0820562030.AUD","LU0882574139.USD","SG9999013999.USD","SG9999018857.SGD","LU1868837300.USD","IE00B4R5TH58.HKD","LU0158827948.USD","LU0786609619.USD","LU1551013342.USD","LU2750360997.AUD","LU1720051017.SGD","LU0320765992.SGD","BK4532","LU1868836757.USD","IE00BZ1G4Q59.USD","LU2089284900.SGD","LU2237443978.SGD","LU2023250504.SGD","LU2168564495.EUR","LU0672654240.SGD","ELIS","BK4588","IE00B4JS1V06.HKD","SG9999014906.USD","LU2361045086.USD","LU2089283258.USD","LU1093756168.USD","LU1814569148.SGD","BK4516","SGXZ31699556.SGD","LU1712237335.SGD","LU1064131342.USD","LU2456880835.USD","IE00BK4W5L77.USD","LU0058720904.USD","LU1145028129.USD","LU1983299246.USD","LU1989771016.USD","LU0820561909.HKD","LU0354030511.USD","LU0079474960.USD","LU2237443549.SGD","LU1232071149.USD","LU1548497426.USD","LU2213496289.HKD","LU2491050071.SGD","SG9999017495.SGD","LU2471134523.USD","LU0234572021.USD","LU0823434740.USD","LU1988902786.USD","LU2471134879.HKD","IE00BKPKM429.USD","LU0385154629.USD","LU2471134952.CNY","LU1057294990.SGD","LU0823434583.USD","BK4534","SGXZ81514606.USD","LU2168564065.EUR","LU1868837136.USD","IE00BJT1NW94.SGD","LU0203202063.USD","IE00BJLML261.HKD","BK4007","LU2461242641.AUD","LU2112291526.USD","LU2491050154.USD","LU2756315664.SGD","SG9999015986.USD","SG9999015978.USD","NVOX","IE00BWXC8680.SGD","BK4581","LU2087625088.SGD","LU2089984988.USD","LU2168564149.EUR","LU2236285917.USD","LU2361044949.HKD","LU2602419157.SGD","IE0009355771.USD","LU0210536198.USD","LU0787776722.HKD","LU1868836914.USD","LU2111349929.HKD","LU0820561818.USD","LU2896262040.SGD","SG9999001176.SGD","SG9999014914.USD","IE00BKDWB100.SGD","LU0094547139.USD","LU0466842654.USD","LU1291159041.SGD","BK4533","LU1127390331.HKD","SG9999015952.SGD","SG9999018865.SGD","LU2168564222.USD","NVOH","SGXZ57979304.SGD","LLY","LU2211815571.USD","IE00BJJMRX11.SGD","LU0106261372.USD","IE00BFSS8Q28.SGD","LU0198837287.USD","LU2552382058.USD","LLII","LU0203201768.USD","SG9999015945.SGD","LU2106854487.HKD","LU2746668974.SGD","IE00BJJMRY28.SGD","LU0266013472.USD","SG9999001176.USD","LU0943347566.SGD","LU0158827781.USD","LU2271345857.HKD","LU1917777945.USD","LU2023250330.USD","SG9999014880.SGD","SG9999014898.SGD","IBB","LU2357305700.SGD","LU0882574055.USD","ADAG","LU2360106947.USD","LU0353189763.USD","LU0964807845.USD","LU2237443465.HKD","LU2468319806.SGD","LU0006306889.USD","IE00BN29S564.USD","LU0823416689.USD","IE00BKVL7J92.USD","XLV","LU2417539215.USD","LU0289739699.SGD","LU1366192091.USD","IE0004445015.USD","LU0417517546.SGD","BK4139","IE0002141913.USD","LU1629891620.HKD","LU1720051108.HKD","LU0889565916.HKD","LU2237443382.USD","LU0109391861.USD","BK7104","LU1069344957.HKD","GB00BDT5M118.USD","LU2264538146.SGD","LU0354030438.USD","LU0114720955.EUR","LU0320765059.SGD","LU1267930730.SGD","LU2462157665.USD","LU2552382215.SGD","IE00BFSS7M15.SGD","LU0256863902.USD","LU2237443622.USD","LU0353189680.USD","LU1035775433.USD","LU1093756325.SGD","LU2028103732.USD","LU2750360641.GBP","LU0323591593.USD","IE0004445239.USD","LU0061475181.USD","LU2023251221.USD","LU2237438978.USD","LU2471134796.USD","IE00B2B36J28.USD","LU0683600562.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509577","title":"Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509577","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509577?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:27","pubTimestamp":1775132820,"startTime":"0","endTime":"0","summary":"Adagene said early clinical trial results showed that its experimental cancer drug, muzastotug, worked better at higher doses when combined with Merck's Keytruda.The biotechnology company found that in its Phase 1b/2 study, the treatment in combination with Merck's pembrolizumab, also known as Keytruda, helped shrink tumors or keep them from growing in some patients with an advanced form of colorectal cancer called microsatellite stable colorectal cancer, that usually doesn't respond to typical immunotherapy.According to the study, muzastotug produced a 31% confirmed overall response rate in patients receiving the 20 milligram-per-kilogram dosing strategy, compared with 13% in the 10 mg-kg cohorts, the company said.Adagene said progression-free survival favored the higher doses.While the company noted there weren't any extreme side effects, it said 4% of trial patients stopped the treatment because of more minor treatment-related adverse events.The Food and Drug Administration has give","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Adagene Drug Shows Stronger Tumor Response at Higher Dose in Early Cancer Trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624650933","title":"Adagene 18.666M share Spot Secondary priced at $3.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2624650933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624650933?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:14","pubTimestamp":1775132085,"startTime":"0","endTime":"0","summary":"Leerink and LifeSci Capital acted as joint book running managers for the offering. Published first on TheFly – the ultimate source for real-time, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-18-666m-share-spot-secondary-priced-at-3-75-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-18-666m-share-spot-secondary-priced-at-3-75-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506698","title":"Adagene enters pact with Incyte for combination of muzastotug, INCA33890","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506698","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506698?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:01","pubTimestamp":1775131288,"startTime":"0","endTime":"0","summary":"Adagene (ADAG) announced a clinical collaboration with Incyte (INCY) to evaluate the combination of muzastotug and INCA33890, a TGFbetaR2 PD-1 bisp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-enters-pact-with-incyte-for-combination-of-muzastotug-inca33890-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-enters-pact-with-incyte-for-combination-of-muzastotug-inca33890-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4550","BK4585","BK4588","ADAG","INCY","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506642","title":"Adagene announces results from the latest data cut of muzastotug study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506642","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506642?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:55","pubTimestamp":1775130900,"startTime":"0","endTime":"0","summary":"Adagene (ADAG) announced results from the latest data cut from its Phase 1b/2 study of muzastotug in patients with advanced microsatellite stable c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-announces-results-from-the-latest-data-cut-of-muzastotug-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-announces-results-from-the-latest-data-cut-of-muzastotug-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505013","title":"Adagene Prices $70 Million ADS Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505013","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505013?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:46","pubTimestamp":1775130418,"startTime":"0","endTime":"0","summary":"Adagene (ADAG) said Thursday that it priced an underwritten public offering of about 18.7 million American depositary shares at $3.75 apiece, for gross proceeds of roughly $70 million.Each ADS represents 1.25 ordinary shares, and the offering is scheduled to close on Monday, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505429","title":"Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505429","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505429?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:38","pubTimestamp":1775129923,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) has issued an update. On April 2, 2026, Adagene reported updated interim data from a Phase 1b/2 study of its masked anti-CTLA-4...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-posts-strong-muzastotug-data-and-incyte-collaboration-in-mss-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-posts-strong-muzastotug-data-and-incyte-collaboration-in-mss-colorectal-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4113","BK4139","INCY","BK4532","BK4588","MSS","BK4585","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505478","title":"Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505478","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505478?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:36","pubTimestamp":1775129802,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) just unveiled an update. On April 2, 2026, Adagene Inc. priced an underwritten public offering of 18,666,000 American depositar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-prices-us70-million-ads-offering-to-bolster-cancer-immunotherapy-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-prices-us70-million-ads-offering-to-bolster-cancer-immunotherapy-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503117","title":"Adagene prices follow-on offering at USD 70 million, ADSs at USD 3.75","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503117","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503117?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:10","pubTimestamp":1775128224,"startTime":"0","endTime":"0","summary":"Adagene priced an underwritten public offering of 18,666,000 ADSs at US$ 3.75 per ADS.Gross proceeds expected at about US$ 70 million.Leerink Partners, LifeSci Capital named joint book-running managers.Investor participation included Janus Henderson Investors, Deerfield Management, Invus.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLbByZw1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2095319765.USD","BK4588","BK4112","LU0054578231.USD","LU2210149790.SGD","SG9999014005.SGD","JHG","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4585","IE00BGHQF748.EUR","MNSH","LU0314104364.USD","ADAG","BK4207","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","BK4135","LU2210150020.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624312503","title":"Adagene, Incyte partner to test muzastotug combo in MSS colorectal cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624312503","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624312503?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:01","pubTimestamp":1775127705,"startTime":"0","endTime":"0","summary":"Adagene entered a clinical collaboration with Incyte to test muzastotug  in combination with Incyte’s INCA33890 in microsatellite stable colorectal cancer patients with or without liver metastases.Incyte will sponsor and run trial, with dose-escalation focused on safety and tolerability followed by efficacy expansion in chemotherapy-refractory patients.Adagene will supply muzastotug for study, positioning drug as potential backbone therapy for next-generation immuno-oncology combinations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3llQgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4532","BK4588","BK4550","BK4585","BK4139","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624505856","title":"Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2624505856","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624505856?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:00","pubTimestamp":1775127600,"startTime":"0","endTime":"0","summary":"Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement ov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/02/3267222/0/en/Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Late-line-Patients-with-Microsatellite-Stable-Colorectal-Cancer-Demonstrate-Improved-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","OS","LU0456854461.SGD","LU0266512127.USD","BK4213","PFS","ADAG","MSS","BK4097","BK4113","CRC","ORR","BK4195","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654782","title":"Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654782","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624654782?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:06","pubTimestamp":1775081198,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) has issued an update. On April 1, 2026, Adagene reported its full-year 2025 results, highlighting encouraging clinical data for...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-posts-2025-results-as-muzastotug-data-partnerships-extend-cash-runway-to-2028?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-posts-2025-results-as-muzastotug-data-partnerships-extend-cash-runway-to-2028?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624544986","title":"Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624544986","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624544986?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:07","pubTimestamp":1775077661,"startTime":"0","endTime":"0","summary":"Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51614894/adagene-fy-adj-eps-0-24-misses-0-15-estimate-sales-7-671m-beat-1-667m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624447905","title":"Adagene reports FY25 EPS (24c) vs (51c) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2624447905","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624447905?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:06","pubTimestamp":1775077568,"startTime":"0","endTime":"0","summary":"Reports FY25 revenue $7.7M vs $103,000 last year. “Our clinical data for muzastotug plus pembrolizumab consistently demonstrate potent, dose-depend...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagene-reports-fy25-eps-24c-vs-51c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagene-reports-fy25-eps-24c-vs-51c-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADAG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624954487","title":"Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624954487","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624954487?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:00","pubTimestamp":1775077200,"startTime":"0","endTime":"0","summary":"In 2025, muzastotug showed 29% confirmed overall response rate  among 21 patients with MSS CRC in the 20 mg/kg dose cohorts. Median overall survival  for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months. 4% overall discontinuation rate, no dose limiting toxicities, and no Grade 4 or 5 treatment-related adverse events  across 67 patients in all dose cohorts supports improved tolerability profile of muzastotug. Randomized Phase 2 trial enrollment ahead of plan, with potential updates in 2026 and results expected in 1H 2027; registration trial expected to begin once optimal dose regimen has been established. Cash and cash equivalents of $74.5 million as of December 31, 2025, plus proceeds raised from the ATM Offering in 2026 year-to-date, anticipated to provide cash runway into early 2028. SAN DIEGO, Calif. and SUZHOU, China, April 01, 2026  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","HCC","BK4006","ADAG","R","ORR","OS","BK4139","BK4232","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620673656","title":"Adagene Inc  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620673656","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620673656?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:40","pubTimestamp":1774010418,"startTime":"0","endTime":"0","summary":"Adagene Inc  expected to post a loss of15cents a share - Earnings Preview Adagene Inc ADAG.OQ, ADAG.O is expected to  report resultson March 23 (estimated) for the period ending September 30 2025LSEG'","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40815N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADAG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0476},{"period":"1month","weight":0.0704},{"period":"3month","weight":1.4837},{"period":"6month","weight":0.9487},{"period":"1year","weight":1.5676},{"period":"ytd","weight":1.0106}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adagene Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Their platform is designed to enable the rapid development of precision immunotherapy candidates, through the identification of predictive biomarkers for patient stratification and preselection.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.330237},{"month":2,"riseRate":0.4,"avgChangeRate":-0.074707},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.132812},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.077299},{"month":5,"riseRate":0.6,"avgChangeRate":0.052249},{"month":6,"riseRate":0.6,"avgChangeRate":-0.017271},{"month":7,"riseRate":0.4,"avgChangeRate":-0.053125},{"month":8,"riseRate":0.6,"avgChangeRate":0.014607},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076447},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090108},{"month":11,"riseRate":0.6,"avgChangeRate":0.034268},{"month":12,"riseRate":0.4,"avgChangeRate":0.020923}],"exchange":"NASDAQ","name":"Adagene","nameEN":"Adagene","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adagene,ADAG,Adagene股票,Adagene股票老虎,Adagene股票老虎国际,Adagene行情,Adagene股票行情,Adagene股价,Adagene股市,Adagene股票价格,Adagene股票交易,Adagene股票购买,Adagene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adagene(ADAG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adagene(ADAG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction